Phase III Trial Results for Veracyte Decipher Test Announced
By United One News · AI-generated summary of 2 outlets' reporting
Published · Updated
AI-generated summary of the coverage listed below:
A phase III trial analysis showed Veracyte’s Decipher prostate test can predict the benefit of adding abiraterone to treatment for high-risk patients.
- Veracyte announced the findings from an analysis of the STAMPEDE study.
- The test identifies patients with clinically very high-risk, nonmetastatic disease.
- The new predictive evidence is scheduled to be presented at ESMO.
Covered by 2 outlets across the spectrum: 0% left, 100% center, 0% right.
How each side framed it
Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer
Timeline
First to report: Globenewswire_fr (); 2 articles from 2 outlets so far.
Who is covering this story
- Center (2): Globenewswire_fr, Pharmabiz
Sources
- Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer — Globenewswire_fr (center, AI-estimated) ·
- Otsuka presents final phase 3 VISIONARY results at ASN demonstrating Voyxact stabilized kidney function and reduced risk of disease progression and kidney failure — Pharmabiz (center, AI-estimated) ·